TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change From Baseline in Specific Imaging Airway Volume (siVaw)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: incidence of post operative nausea and vomiting
Endpoint domain: Adverse events/effects
Primary endpoint: Scapular Notching
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: left without being seen
Endpoint domain: Adverse events/effects
Primary endpoint: return to ED after discharge
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Forearm blood flow (FBF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Abdominal Pain Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Postprandial appetite response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Subsequent energy consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Passive Stiffness Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Circuit lifespan during continuous renal replacement therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Flap success or failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Maximum Interburst Interval on cEEG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Lower Margin Amplitude on aEEG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Participants With Clinical Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean Number of Blood Transfusions Per Visit
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Oxidant / Antioxidant Enzyme Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proteoglycan Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADAMTS Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline Staphylococcus count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: change in Perfusion Index (PI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Bone Infection
Endpoint domain: Adverse events/effects
Primary endpoint: plasma concentration ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Function related to knee
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pain related to knee
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Mobility
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Diagnosis of chest infection within 7 days after stroke
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Pain Score From Baseline to 30 Minutes Pre-procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pain Score From Baseline to 2 Weeks Post-procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pain Score From Baseline to 3 Months Post-procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metabolizable energy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fermentability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum Thromboxane Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Meibomian gland score (MGS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Meibomian gland yielding liquid secretions (MGYLS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ocular Surface Disease Index Score (OSDI)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Type, severity and incidence of ocular and systemic adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Difference in inflammatory markers (CRP, WBC differential count, IL-6, TGF-β)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Subjective assessment of swallowing function (dysphagia)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective assessment of swallowing function (dysphagia)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of clinical events with HFRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of mortalities
Endpoint domain: Mortality/survival
Primary endpoint: Number of patients with accurate sentinel lymph node status prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Sensitivity of Sentinel Lymph Node Sampling Method
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of Sentinel Lymph Node Sampling Method
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microbiological effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change From Baseline in Modified Motor Score (mMS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Response Rate (Complete Response [CR] and Partial Response [PR])
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Disease Control Rate (Complete Response [CR], Partial Response [PR], and Stable Disease [SD])
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Extent of hair preservation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lactic Acidosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cmax: Maximum Observed Plasma Concentration for TAK-385
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-385
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-120): Area Under the Plasma Concentration-time Curve From Time 0 to 120 Hours Postdose for TAK-385
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-385
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Natural Killer Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from baseline of the Unified Parkinson Disease Rating Scale part III score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Concordance of patient-collected and clinician-collected wet mounts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in YMRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systolic Blood Pressure Readings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: BOLD signal in the insula and somatosensory cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of screening tests for excessive alcohol consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of brief interventions for excessive alcohol consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Blood loss during cesarean sections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Prevalence of chronic kidney disease stage >= 4 (raw number)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Prevalence of chronic kidney disease stage >= 4 (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Identification of new variants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and efficacy of laparoscopic RYGB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Intraocular Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum total B12 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lesion numbers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Standard uptake value (SUV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Specific Image-based Airway Volume (siVaw)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Specific Image-based Airway Resistance (siRaw)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of children anesthetized
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Serum Zonulin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Iowa Gambling Test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of participants with amikacin PK/PD target attainment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Subjective Sleep Latency
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Gait performances
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in body composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in frequency of anxiety symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in severity of anxiety symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pharmacokinetics of epinephrine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NIH chronic prostatitis symptom index
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Tumor-infiltrating Lymphocytes (TILs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in plasma IL-6 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Adverse Events (AEs) and Adverse Drug Reactions (ADRs)
Endpoint domain: Adverse events/effects
Primary endpoint: changes in urine protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence of autonomic nervous system dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Laxations Per Subject Within 24 Hours of Dosing Per Week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rate of Grade 2,3,4 Diarrhea
Endpoint domain: Adverse events/effects
Primary endpoint: Resource Use of Asthma patients
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Chronic Postoperative Pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of Participants Responded for ASAS20
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Standard Snellen acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Improvement in visual fields
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of AEs, SAEs, and discontinuation due to AE
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical Global Impressions-Severity of Illness (CGI-S) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Nine hole peg test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of early lung tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Expression of hCG Target NOTCH1 Protein by IHC in Endometrial Glands
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression of hCG Target NOTCH1 Protein by IHC in Endometrial Stroma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression of hCG Target C3 Protein by IHC in Endometrial Stroma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change From Baseline in the Mean Diurnal Trabecular Outflow Facility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Mean Percent Change From Baseline in the Mean Diurnal Trabecular Outflow Facility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Occurrence of serious and/or unexpected adverse reactions
Endpoint domain: Adverse events/effects
Primary endpoint: verbal fluency
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cerebral oximetry readings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Emergency agitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Regional recurrence-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Distant recurrence-free survival
Endpoint domain: Mortality/survival
Primary endpoint: post bronchodilator FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in QTcF duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: IOL Centration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of revisions
Endpoint domain: Adverse events/effects
Primary endpoint: Number of days of hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Incidence of co-morbidities
Endpoint domain: Adverse events/effects
Primary endpoint: Urethral stricture
Endpoint domain: Adverse events/effects
Primary endpoint: Muscle Recruitment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30 Meter sprint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ground Reaction force (flight time)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morbidity at 60 days postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of surgically induced astigmatism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC Postprandial Glucagon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Salivary flow measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Insulin Sensitivity Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Visceral Fat Mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Comparison of bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Change in prealbumin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Overall Comfort by Visit
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Overall Quality of Vision by Visit
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Average Comfortable Daily Wear Time by Visit
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Postoperative delirium rate
Endpoint domain: Adverse events/effects
Primary endpoint: Phlebitis incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Laboratory-confirmed influenza-associated hospitalised illness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of intraocular lowering from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of IOP lowering agents required to achieve goal IOP
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of progression to further glaucoma surgeries
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients Requiring Continuous Lorazepam Infusion
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Patients Requiring ICU Admission
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Total Lorazepam Required Per Patient Per Admission
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Score on Hamilton Depression Rating Scale (HAM-D)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Classification Algorithm Error Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with cancer care communication
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: outcome of IHs in patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biologic Activity of Prohibitin-TP01
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Adverse events following inhaled single dose of AIR-DNase
Endpoint domain: Adverse events/effects
Primary endpoint: Adverse events following inhaled multiple doses of AIR-DNase
Endpoint domain: Adverse events/effects
Primary endpoint: Youth Symptoms & Functioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Caregiver Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Time to occurrence of AKs
Endpoint domain: Mortality/survival
Primary endpoint: Time to occurrence of NMSC
Endpoint domain: Mortality/survival
Primary endpoint: anti-IIa and Argatroban dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: anti-Xa values and heparin dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: admission to ICU
Endpoint domain: Mortality/survival
Primary endpoint: Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants Who Developed Delirium
Endpoint domain: Adverse events/effects
Primary endpoint: Affect Recognition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Verbal Working Memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With IGA Score of 0 or 1 at Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Experienced a 75% Reduction in EASI at Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antibody Response to the Vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of subjects with at least 50% MASI score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SARA score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Patients Failing Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Reduction of eGFR at One Year by More Than 15%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Progression in Fibrosis Score at One Year by >=20%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in aerobic exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of correct final diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NIHSS (National Institutes of Health Stroke Scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Rankin scale (Modified Rankin Scale)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Smoking relapse
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: First week seroma drainage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time to judge resectability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Weight Change From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Depression, as Assessed by Hamilton Depression Rating Scale (Ham-D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alteration in intermediate biomarkers of breast cancer risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Psychological Distress (Anxiety and Depression)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Capabilities of Activities of Daily Living
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Fluoride use compliance
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Serious Adverse Events and Adverse Events Leading to Withdrawal
Endpoint domain: Adverse events/effects